Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-acid glycoprotein

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3248-3253

  Fuse, Eiichi ^a   Tanii, Hiromi ^a   Kurata, Noriaki ^a   Kobayashi, Hiroyuki ^a   Shimada, Yasuhiro ^b   Tamura, Tomohide ^b   Sasaki, Yasutsuna ^c   Tanigawara, Yusuke ^d   Lush, Richard D ^e   Headlee, Donna ^e   Figg, William D ^e   Arbuck, Susan G ^f   Senderowicz, Adrian M ^f   Sausville, Edward A ^f   Akinaga, Shiro ^a   Kuwabara, Takashi ^a   Kobayashi, Satoshi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d KOBE UNIVERSITY   (Japan)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Div of Cancer Treatm and Diagnosis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; OROSOMUCOID;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; DOGS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED BALB C; OROSOMUCOID; PROTEIN BINDING; RATS; SERUM ALBUMIN; STAUROSPORINE; SUBSTRATE SPECIFICITY;

EID: 0032145499     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Lush, R. M., Senderowicz, A. M., Figg, W. D., Headlee, D., Inoue, K., and Sausville, E. A. Surprising pharmacokinetics of UCN-01 in patients with refractory neoplasms may be due to high degree of protein binding. Proc. Am. Assoc. Cancer Res., 38: 4029, 1997.
2. th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium, p. 21, 1997.
3. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 51: 4888-4892, 1991.
4. Seynaeve, C. M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., and Worland, P. J. Cell cycle arrest and inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53: 2081-2086, 1993.
5. Takahashi, I., Kobayashi, E., Asano, K., Yoshida, M., and Nakano, H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J. Antibiot. (Tokyo), 40: 1782-1784, 1987.
6. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32: 183-189, 1993.
7. Kawakami, K., Futami, H., Takahara, J., and Yamaguchi, K. UCN-01, 7-hydroxylstaurosporine, inhibits kinase activity of cyclin-dependent kinase and reduces the phosphorylation of the retinoblastoma susceptibility gene product in an A549 human lung carcinoma cell line. Biochem. Biophys. Res. Commun., 219: 778-783, 1996.
8. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/ Cip/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res., 57: 1495-1501, 1997.
9. Akinaga. S., Nomura, K., Gomi, K., and Okabe, M. Synergistic antitumor effect of UCN-01, a protein kinase (C) inhibitor, combined with various anti-cancer agents. Proc. Am. Assoc. Cancer Res., 33: 3072, 1992.
10. Shao, R. G., Cao, C. X., Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res., 57: 4029-4035, 1997.
11. Bombardt, P. A., Brewer, J. E., and Johnson, M. G. Protein binding of tirilazad (U-74006) in human, Sprague-Dawley rat, Beagle dog and cynomolgus monkey serum. J. Pharmacol. Exp. Ther., 269: 145-150, 1994.
12. Parker, R. B., Williams, C. L., Laizure, S. C., and Lima, J. J. Factors affecting serum protein binding of cocaine in humans. J. Pharmacol. Exp. Ther., 275: 605-610, 1995.
13. Yamaoka, K., Tanigawara, Y., Nakagawa, T., and Uno, T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-dyn. 4: 879-885, 1981.
14. Kurata, N., Kuramitsu, T., Tanii, H., Fuse, E., Kuwabara, T., Kobayashi, H., and Kobayashi, S. Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01 in human plasma or urine. J. Chromatogr. 708: 223-227, 1998.
15. Gibaldi, M., and Perrier, D. Noncompartmental analysis based on statistical moment theory. In: M. Gibaldi and D. Perrier (eds.), Pharmacokinetics, pp. 409-417. New York: Marcel Dekker, 1982.
16. Watari, N., and Benet, L. Z. Determinant of mean input time, mean residence time, and steady-state volume of distribution with multiple drug inputs. J. Pharmacokinet. Biopharm. 17: 593-599, 1989.
17. Wilkinson, G. R. Plasma and tissue binding considerations in drug disposition. Drug Metab. Rev., 14: 427-465, 1983.
18. 125I-labelled human α-1-acid glycoprotein. Clin. Pharmacokinet., 11: 336-342, 1986.
19. Kremer, J. M. H., Wilting, J., and Janssen, L. H. M. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev., 40: 1-47, 1988.
20. Lin, J. H. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos., 23: 1008-1021, 1995.
21. Yoo, S. D., Holladay, J. W., Fincher, T. K., Baumann, H., and Dewey, M. J. Altered disposition and antidepressant of imipramine in transgenic mice with elevated α-1-acid glycoprotein. J. Pharmacol. Exp. Ther., 276: 918-922, 1996.